Prions were initially discovered in studies of scrapie, a transmissible neurodegenerative disease (ND) of sheep and goats thought to be caused by slow viruses. Once scrapie was transmitted to rodents, it was discovered that the scrapie pathogen resisted inactivation by procedures that modify nucleic acids. Eventually, this novel pathogen proved to be a protein of 209 amino acids, which is encoded by a chromosomal gene. After the absence of a nucleic acid within the scrapie agent was established, the mechanism of infectivity posed a conundrum and eliminated a hypothetical virus. Subsequently, the infectious scrapie prion protein (PrPSc) enriched for β-sheet was found to be generated from the cellular prion protein (PrPC) that is predominantly α-helical. The post-translational process that features in nascent prion formation involves a templated conformational change in PrPC that results in an infectious copy of PrPSc. Thus, prions are proteins that adopt alternative conformations, which are self-propagating and found in organisms ranging from yeast to humans. Prions have been found in both Alzheimer's (AD) and Parkinson's (PD) diseases. Mutations in APP and α-synuclein genes have been shown to cause familial AD and PD. Recently, AD was found to be a double prion disorder: both Aβ and tau prions feature in this ND. Increasing evidence argues for α-synuclein prions as the cause of PD, multiple system atrophy, and Lewy body dementia.
Skip Nav Destination
Article navigation
September 2020
Issue Editors
-
Cover Image
Cover Image
This issue of Emerging Topics in Life Sciences is guest edited by Richard Reece, and celebrates 10 years of the Royal Society of Biology. The cover features a photograph submitted by Claire Kremen, who's article discusses how the silvopastoral system in Colombia restores connectivity to landscapes and improves conditions for biodiversity while providing cattle farmers with improved productivity and profitability. Photograph by Andrés Felipe Zuluaga Salazar, The Nature Conservancy.
Perspective|
August 17 2020
Expanding spectrum of prion diseases Available to Purchase
Jacob I. Ayers;
Jacob I. Ayers
1Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, U.S.A.
2Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, U.S.A.
Search for other works by this author on:
Nick A. Paras;
Nick A. Paras
1Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, U.S.A.
2Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, U.S.A.
Search for other works by this author on:
Stanley B. Prusiner
1Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, U.S.A.
2Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, U.S.A.
3Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, U.S.A.
Correspondence: Stanley B. Prusiner ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 2397-8562
Print ISSN: 2397-8554
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology
2020
Emerg Top Life Sci (2020) 4 (2): 155–167.
Citation
Jacob I. Ayers, Nick A. Paras, Stanley B. Prusiner; Expanding spectrum of prion diseases. Emerg Top Life Sci 8 September 2020; 4 (2): 155–167. doi: https://doi.org/10.1042/ETLS20200037
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.